Generics Cos. Get More Freedom In High Court Patent Ruling

The U.S. Supreme Court’s decision Thursday shutting down a patent case involving a generic heart drug that uses a so-called skinny label establishes a road map for generics companies to avoid such suits and creates hurdles for branded companies pursuing infringement litigation, attorneys say.

Continue reading →